Pharmaceuticals

Biosimilar Contract Manufacturing Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar contract manufacturing market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Biosimilar Contract Manufacturing Market?

The biosimilar contract manufacturing market has experienced rapid expansion over recent years. This market is projected to expand from $9.94 billion in 2025 to $11.49 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 15.7%. Historically, this expansion has been driven by factors such as the expiry of reference biologic patents, the early implementation of biosimilar development initiatives, the broadening of contract manufacturing collaborations, enhanced regulatory directives concerning biosimilars, and a rise in the occurrence of chronic diseases.

The biosimilar contract manufacturing market is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a valuation of $20.35 billion, demonstrating a compound annual growth rate (CAGR) of 15.4%. This anticipated growth during the forecast period is driven by several factors, including the increasing number of biosimilar approvals globally, the escalating demand to lower biologic treatment expenses, the broadening of biosimilar product pipelines, heightened investments in large-scale manufacturing capabilities, and improvements in process optimization technologies. Key trends emerging over the forecast period encompass a greater reliance on outsourcing biosimilar production, an escalating need for economical production platforms, a strengthened emphasis on analytical and quality control provisions, the expansion of manufacturing processes utilizing mammalian cells, and an intensified focus on adherence to regulatory standards.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp

Which Drivers Are Supporting The Rise Of The Biosimilar Contract Manufacturing Market?

The rising incidence of diabetes is anticipated to drive the expansion of the biosimilar contract manufacturing market in the future. Diabetes prevalence signifies the portion of a population living with the condition at any given moment, indicating a continuous requirement for treatment and lifelong therapeutic needs. This increase in diabetes cases stems from increasingly inactive lifestyles and unhealthy eating patterns, which contribute to obesity, insulin resistance, and a greater occurrence of type 2 diabetes. Biosimilar contract manufacturing plays a crucial role in managing diabetes by facilitating the economical, large-scale creation of biosimilar insulin and associated biologics. This process guarantees uniform quality and adherence to regulations, thereby making sophisticated treatments more readily available to patients. Consequently, it boosts treatment affordability and broadens global access to vital diabetes care. For example, in June 2024, data from the National Health Service, a UK-based government body, showed that 3,615,330 people registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% rise from 3,065,825 instances in 2022. Thus, the increasing prevalence of diabetes is fueling the growth of the biosimilar contract manufacturing market.

What Leading Segments Are Studied In The Biosimilar Contract Manufacturing Market?

The biosimilar contract manufacturing market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Other Product Types

2) By Service Type: Process Development, Analytical And Quality Control, Fill And Finish Operations, Packaging, Other Service Types

3) By Source: Mammalian, Non-mammalian

4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

5) By End-Use: Pharmaceutical Companies, Biotech Companies

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Insulin: Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin

3) By Erythropoietin: Alpha Erythropoietin, Beta Erythropoietin, Darbepoetin Alfa, Continuous Erythropoietin Receptor Activators

4) By Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, Long Acting Granulocyte Colony-Stimulating Factor

5) By Other Product Types: Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, Hormonal Biologics

Which Trends Are Influencing The Performance And Direction Of The Biosimilar Contract Manufacturing Market?

Leading companies in the biosimilar contract manufacturing market are prioritizing the creation of advanced production facilities, particularly mirrored single-use plants, to speed up technology transfer, improve scalability, and ensure commercial dependability. These mirrored single-use plants consist of identical production suites that operate with disposable bioprocess equipment and integrated digital systems, facilitating quick changes, uniform quality across multiple sites, and a lower risk of contamination. For example, in September 2025, Rezon Bio, a contract development and manufacturing organization (CDMO) from Poland, inaugurated two single-use biomanufacturing sites with mirrored capabilities, spanning from cell line development to commercial GMP supply. This method allows for more rapid technology transfer and flexible scale-up for biosimilars with reduced operational interruptions, concurrently enhancing batch-to-batch consistency through standardized suites, embedded analytics, and automated logistics. It also contributes to a lower total cost of ownership for sponsors by minimizing cleaning validation needs, shortening development and manufacturing periods, and reducing the risks associated with expansion.

Which Key Market Players Are Investing In Expansion And Innovation Within The Biosimilar Contract Manufacturing Market?

Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-biosimilar-contract-manufacturing-market-report

Which Regions Are Poised For Strategic Growth In The Biosimilar Contract Manufacturing Market?

North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilar Contract Manufacturing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30215&type=smp

Browse Through More Reports Similar to the Global Biosimilar Contract Manufacturing Market 2026, By The Business Research Company

Biopharmaceuticals Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Medical Device Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-device-contract-manufacturing-global-market-report

Food Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/food-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795